Trial Profile
Phase Ib study of durvalumab (MEDI 4736) in combination with anti-CD19 CAR transduced T cells in patients with patients with non-Hodgkin's lymphoma
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; JCAR 014 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors AstraZeneca; Juno Therapeutics; MedImmune
- 28 Apr 2015 New trial record
- 23 Apr 2015 MedImmune and Juno Therapeutics have announced an immuno-oncology clinical trial collaboration and will jointly co-fund this initial phase Ib study, which is expected to begin in 2015, according to a media release.